Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611556 · ClinicalTrials.gov registry record · Phase 1
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 213
- Enrollment target
NCT03611556 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 213 participants.
The verdict
NCT03611556, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 213 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Interventions
- DRUG Oxaliplatin
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Durvalumab
- DRUG Oleclumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2022-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611556
The ClinicalTrials.gov registry entry for NCT03611556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT03611556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03611556 about?
NCT03611556 is a clinical study titled "MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.". The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
What is the current status of trial NCT03611556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2018-06-21. Estimated completion is 2022-07-22.
What interventions are being tested in trial NCT03611556?
The interventions under investigation include: Oxaliplatin (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Durvalumab (DRUG), Oleclumab (DRUG).
Who is sponsoring clinical trial NCT03611556?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.